Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists

Baba, 1999, A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity, Proc Natl Acad Sci U S A, 96, 5698, 10.1073/pnas.96.10.5698

Berman, 2000, The Protein Data Bank, Nucleic Acids Res, 28, 235, 10.1093/nar/28.1.235

Blanpain, 1999, Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein, J Biol Chem, 274, 34719, 10.1074/jbc.274.49.34719

Bower, 1997, Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool, J Mol Biol, 267, 1268, 10.1006/jmbi.1997.0926

Crabb, 2006, GlaxoSmithKline ends aplaviroc trials, AIDS, 20, 641, 10.1097/01.aids.0000216362.59657.96

Doranz, 1997, Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1, J Virol, 71, 6305, 10.1128/jvi.71.9.6305-6314.1997

Dorr, 2005, Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity, Antimicrob Agents Chemother, 49, 4721, 10.1128/AAC.49.11.4721-4732.2005

Dragic, 2001, An overview of the determinants of CCR5 and CXCR4 co-receptor function, J Gen Virol, 82, 1807, 10.1099/0022-1317-82-8-1807

Dragic, 1998, Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry, J Virol, 72, 279, 10.1128/JVI.72.1.279-285.1998

Dragic, 2000, A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5, Proc Natl Acad Sci U S A, 97, 5639, 10.1073/pnas.090576697

Farzan, 1998, A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5, J Virol, 72, 1160, 10.1128/JVI.72.2.1160-1164.1998

Fätkenheuer, 2005, Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1, Nat Med, 11, 1170, 10.1038/nm1319

Fechteler, 1995, Prediction of protein three-dimensional structures in insertion and deletion regions: a procedure for searching data bases of representative protein fragments using geometric scoring criteria, J Mol Biol, 253, 114, 10.1006/jmbi.1995.0540

Howard, 1999, Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function, J Biol Chem, 274, 16228, 10.1074/jbc.274.23.16228

Imamura, 2006, Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity, J Med Chem, 49, 2784, 10.1021/jm051034q

Ji, 2006, Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression, J Biomol Screen, 11, 65, 10.1177/1087057105282959

Jones, 1986, Using known substructures in protein model building and crystallography, EMBO J, 5, 819, 10.1002/j.1460-2075.1986.tb04287.x

Laskowski, 1993, Main-chain bond lengths and bond angles in protein structures, J Mol Biol, 231, 1049, 10.1006/jmbi.1993.1351

Levitt, 1992, Accurate modeling of protein conformation by automatic segment matching, J Mol Biol, 226, 507, 10.1016/0022-2836(92)90964-L

Maeda, 2006, Structural and molecular interactions of CCR5 inhibitors with CCR5, J Biol Chem, 281, 12688, 10.1074/jbc.M512688200

Maeda, 2004, Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro, J Virol, 78, 8654, 10.1128/JVI.78.16.8654-8662.2004

Marozsan, 2005, Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D), Virology, 338, 182, 10.1016/j.virol.2005.04.035

Mirzadegan, 2000, Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle, J Biol Chem, 275, 25562, 10.1074/jbc.M000692200

Morris, 1992, Stereochemical quality of protein structure coordinates, Proteins, 12, 345, 10.1002/prot.340120407

Nakata, 2005, Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model, J Virol, 79, 2087, 10.1128/JVI.79.4.2087-2096.2005

Nishikawa, 2005, Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5, Antimicrob Agents Chemother, 49, 4708, 10.1128/AAC.49.11.4708-4715.2005

Palani, 2002, Synthesis, SAR, and biological evaluation of oximinopiperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity, J Med Chem, 45, 3143, 10.1021/jm0200815

Rabut, 1998, Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1, J Virol, 72, 3464, 10.1128/JVI.72.4.3464-3468.1998

Ross, 1998, Multiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates, J Virol, 72, 1918, 10.1128/JVI.72.3.1918-1924.1998

Rucker, 1996, Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity, Cell, 87, 437, 10.1016/S0092-8674(00)81364-1

Seibert, 2006, Interaction of small molecule inhibitors of HIV-1 entry with CCR5, Virology, 349, 41, 10.1016/j.virol.2006.01.018

Seto, 2006, Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety, J Med Chem, 49, 2037, 10.1021/jm0509703

Strizki, 2005, Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1, Antimicrob Agents Chemother, 49, 4911, 10.1128/AAC.49.12.4911-4919.2005

Tagat, 2004, J Med Chem, 47, 2405, 10.1021/jm0304515

Thompson, 1994, CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res, 22, 4673, 10.1093/nar/22.22.4673

Tsamis, 2003, Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry, J Virol, 77, 5201, 10.1128/JVI.77.9.5201-5208.2003

Watson, 2005, The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor, Mol Pharmacol, 67, 1268, 10.1124/mol.104.008565

Westby, 2007, Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry, J Virol, 81, 2359, 10.1128/JVI.02006-06

Wood, 2005, The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS, Prog Med Chem, 43, 239, 10.1016/S0079-6468(05)43007-6